{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:55:14Z","timestamp":1760151314951,"version":"build-2065373602"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1055\/a-2324-5473","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:12Z","timestamp":1760135832000},"page":"1294-1308","source":"Crossref","is-referenced-by-count":0,"title":["Erstlinienbehandlung \u00e4lterer Patienten mit CLL: Ein neuer Ansatz ohne Chemotherapie"],"prefix":"10.1055","volume":"150","author":[{"given":"Jan Christoph","family":"Banck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"F\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela A.","family":"Hoechstetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy","volume":"100","author":"M Hallek","year":"2025","journal-title":"Am J Hematol"},{"issue":"10","key":"ref2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41408-021-00556-7","article-title":"Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany","volume":"11","author":"H Kaj\u00fcter","year":"2021","journal-title":"Blood Cancer J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"P Strati","year":"2015","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia 5 on behalf of the ESMO Guidelines Committee","volume":"35","author":"B Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1182\/blood-2023-174289","article-title":"Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed\/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R\/R CLL\/SLL)","volume":"142","author":"JR Brown","year":"2023","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"CU Niemann","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s11912-022-01322-z","article-title":"How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?","volume":"24","author":"JM Rhodes","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1182\/blood.2023020195","article-title":"Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL","volume":"142","author":"L der Straten","year":"2023","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104428","article-title":"Safety profile of first-line targeted therapies in elderly and\/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis","volume":"201","author":"A Sto\u017cek-Tutro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer","volume":"32","author":"H Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"26","key":"ref13","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"JA Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood-2015-04-585067","article-title":"Initial treatment of CLL: integrating biology and functional status","volume":"126","author":"N Jain","year":"2015","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"A Condoluci","year":"2020","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1182\/blood-2024-200848","article-title":"Efficacy and Safety of Acalabrutinib Treatment in Very Old (\u226580y) and\/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) \u2013 Primary Endpoint Analysis of the Phase II CLL-Frail Trial","volume":"144","author":"F Simon","year":"2024","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials","volume":"99","author":"V Goede","year":"2014","journal-title":"Haematologica"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"P Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"10","key":"ref19","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/j.1532-5415.2008.01935.x","article-title":"A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients","volume":"56","author":"F Salvi","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"17","key":"ref20","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","article-title":"The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model","volume":"27","author":"MJ Gordon","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","article-title":"Frailty: implications for clinical practice and public health","volume":"394","author":"EO Hoogendijk","year":"2019","journal-title":"Lancet"},{"issue":"06","key":"ref22","doi-asserted-by":"publisher","first-page":"101538","DOI":"10.1016\/j.jgo.2023.101538","article-title":"Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia","volume":"14","author":"PC Johnson","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"04","key":"ref23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group","volume":"57","author":"V Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"03","key":"ref24","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.m146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"LP Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"06","key":"ref25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jamda.2013.03.022","article-title":"Frailty Consensus: a Call to action","volume":"14","author":"JE Morley","year":"2013","journal-title":"J Am Med Dir Assoc"},{"issue":"01","key":"ref27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-020-00870-w","article-title":"Ibrutinib dose modifications in the management of CLL","volume":"13","author":"C Hardy-Abeloos","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"11","key":"ref28","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s12325-018-0793-y","article-title":"Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors","volume":"35","author":"SK Agarwal","year":"2018","journal-title":"Adv Ther"},{"issue":"04","key":"ref29","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"JP Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"08","key":"ref30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"CS Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood-2024-198147","article-title":"BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"144","author":"JP Sharman","year":"2024","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028550","article-title":"Acalabrutinib treatment for older (\u226580 years old) and\/or frail patients with CLL: primary end point analysis of the CLL-Frail trial","author":"F Simon","year":"2025","journal-title":"Blood"},{"issue":"23","key":"ref33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Medical Conditions","volume":"380","author":"K Fischer","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"ref34","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"CU Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"08","key":"ref35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia","volume":"392","author":"JR Brown","year":"2025","journal-title":"N Engl J Med"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2324-5473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:23Z","timestamp":1760135843000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2324-5473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2324-5473","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}